AAT Research appoints Wolfgang Storf to lead expansion

Malta-based group AAT Research has appointed Wolfgang Storf as its new chief executive officer.

Storf joins from MS Pharma Group, where he served as chief strategy officer, and has previously served as CEO of Novartis' Sandoz division in South Africa and held senior management positions with Apotex and Johnson & Johnson.

In his new role he will be tasked with consolidating AAT's internationalisation strategy and leading its expansion into new markets.

Storf said: “I am delighted to take over as CEO at this important stage of AAT's growth, and I'm looking forward to working with the executive team and the board to help the company realise its full potential, enter new markets and establish our products as leading therapies and services for patients and medical professionals respectively.”

His appointment at AAT, which designs and develops medical solutions in neuroscience, will see founder and former CEO Dr Adrian Attard Trevsisan become to the group's chief scientific officer.

Dr Attard Trevisan said: “We have come a long way from a small one-room setup. As the company continues to grow and increase its international footprint, we felt the need to bring in a senior executive who has extensive international experience in the pharmaceutical and medical industries.

He added that his own focus would now be on research, innovation and product development.